A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy

Blood

Volumn 126, Issue 6, 2015, Pages 757-765

  Bonaud, Amélie ^a,b   Bender, Sébastien ^a,b   Touchard, Guy ^c   Lacombe, Corinne ^b,c   Srour, Nivine ^a   Delpy, Laurent ^a   Oblet, Christelle ^a   Druilhe, Anne ^a   Quellard, Nathalie ^b,c   Javaugue, Vincent ^b,c   Cogné, Michel ^a   Bridoux, Frank ^a,b,c   Sirac, Christophe ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DELETION; GENETIC TRANSCRIPTION; HEAVY CHAIN DISEASE; IMMUNOGLOBULIN PRODUCTION; KIDNEY INJURY; MOUSE; MOUSE MODEL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; TRANSGENIC MOUSE; UNFOLDED PROTEIN RESPONSE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENE LOCUS; GENETICS; GLOMERULUS; HUMAN; IMMUNOLOGY; KIDNEY DISEASES; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENETIC LOCI; HEAVY CHAIN DISEASE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PLASMA CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN STRUCTURE, TERTIARY; PYRAZINES; SEQUENCE DELETION; UNFOLDED PROTEIN RESPONSE;

EID: 84940069082     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-630277     Document Type: Article

References (62)

1. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-2530.
2. Leung N, Bridoux F, Hutchison CA, et al International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-4295.
3. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13(6):1235-1248.
4. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12(7):1482-1492.
5. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231-239.
6. Bridoux F, Leung N, Hutchison CA, et al International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698-711.
7. Preud'homme JL, Aucouturier P, Touchard G, et al. Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. Int J Immunopharmacol. 1994;16(5-6):425-431.
8. Aucouturier P, Khamlichi AA, Touchard G, et al. Brief report: heavy-chain deposition disease. N Engl J Med. 1993;329(19):1389-1393.
9. Khamlichi AA, Aucouturier P, Preud'homme JL, Cogné M. Structure of abnormal heavy chains in human heavy-chain-deposition disease. Eur J Biochem. 1995;229(1):54-60.
10. Tubbs RR, Berkley V, Valenzuela R, et al. Pseudo-gamma heavy chain (IgG4 lambda) deposition disease. Mod Pathol. 1992;5(2):185-190.
11. Moulin B, Deret S, Mariette X, et al. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. J Am Soc Nephrol. 1999;10(3):519-528.
12. Denoroy L, Déret S, Aucouturier P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol Lett. 1994;42(1-2):63-66.
13. Déret S, Chomilier J, Huang DB, Preud'homme JL, Stevens FJ, Aucouturier P. Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. Protein Eng. 1997;10(10):1191-1197.
14. Rocca A, Khamlichi AA, Aucouturier P, et al. Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease. Clin Exp Immunol. 1993;91(3):506-509.
15. Decourt C, Cogné M, Rocca A. Structural peculiarities of a truncated V kappa III immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol. 1996;106(2):357-361.
16. Decourt C, Touchard G, Preud'homme J-L, et al. Complete primary sequences of two λ immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease. Am J Pathol. 1998;153(1):313-318.
17. Kaplan B, Livneh A, Gallo G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br J Haematol. 2007;136(5):723-728.
18. Kaplan B, Ramirez-Alvarado M, Dispenzieri A, et al. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med. 2008;46(3):335-341.
19. Soma J, Sato K, Sakuma T, et al. Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis. 2004;43(1):E10-E16.
20. Hendershot L, Bole D, Köhler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol. 1987;104(3):761-767.
21. Zou X, Osborn MJ, Bolland DJ, et al. Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice. J Exp Med. 2007;204(13):3271-3283.
22. Feige MJ, Hendershot LM, Buchner J. How antibodies fold. Trends Biochem Sci. 2010;35(4):189-198.
23. Cogné M, Silvain C, Khamlichi AA, Preud'homme JL. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood. 1992;79(9):2181-2195.
24. Herrera GA, Shultz JJ, Soong SJ, Sanders PW. Growth factors in monoclonal light-chain-related renal diseases. Hum Pathol. 1994;25(9):883-892.
25. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol. 1995;147(2):375-385.
26. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84(10):1322-1338.
27. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int. 2005;68(4):1590-1603.
28. Keeling J, Herrera GA. An in vitro model of light chain deposition disease. Kidney Int. 2009;75(6):634-645.
29. Russell WJ, Cardelli J, Harris E, Baier RJ, Herrera GA. Monoclonal light chain-mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest. 2001;81(5):689-703.
30. Ronco P, Plaisier E, Aucouturier P. Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases. Contrib Nephrol. 2011;169:221-231.
31. Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1(6):1342-1350.
32. Yang CW, Hattori M, Vlassara H, et al. Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol. 1995;5(8):1610-1617.
33. Herrera GA, Russell WJ, Isaac J, et al. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol. 1999;23(2):107-126.
34. Khamlichi AA, Rocca A, Touchard G, Aucouturier P, Preud'homme JL, Cogné M. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood. 1995;86(10):3655-3659.
35. Decourt C, Rocca A, Bridoux F, et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood. 1999;94(10):3559-3566.
36. Sirac C, Bridoux F, Carrion C, et al. Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood. 2006;108(2):536-543.
37. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5(3):317-327.
38. Mallipattu SK, Gallagher EJ, LeRoith D, et al. Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2014;306(9):F1008-F1017.
39. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748-755.
40. Lechouane F, Bonaud A, Delpy L, et al. B-cell receptor signal strength influences terminal differentiation. Eur J Immunol. 2013;43(3):619-628.
41. Bridoux F, Sirac C, Hugue V, et al. Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am J Kidney Dis. 2005;45(4):749-757.
42. Hendershot LM. Immunoglobulin heavy chain and binding protein complexes are dissociated in vivo by light chain addition. J Cell Biol. 1990;111(3):829-837.
43. Haas IG, Wabl M. Immunoglobulin heavy chain binding protein. Nature. 1983;306(5941):387-389.
44. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390.
45. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
46. Shah G, Kaul E, Fallo S, et al. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther. 2013;35(10):1614-1620.
47. Kikukawa Y, Yuki H, Hirata S, et al. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. Int J Hematol. 2015;101(2):133-139.
48. Patel K, Dillon JJ, Leung N, et al. Use of bortezomib in heavy-chain deposition disease: a report of 3 cases. Am J Kidney Dis. 2014;64(1):123-127.
49. Ma Y, Shimizu Y, Mann MJ, Jin Y, Hendershot LM. Plasma cell differentiation initiates a limited ER stress response by specifically suppressing the PERK-dependent branch of the unfolded protein response. Cell Stress Chaperones. 2010;15(3):281-293.
50. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ. Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int. 1998;54(6):1999-2007.
51. Qi Z, Fujita H, Jin J, et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes. 2005;54(9):2628-2637.
52. Ma L-J, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int. 2003;64(1):350-355.
53. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725.
54. Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D'agati VD. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis. 1999;33(5):954-962.
55. Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040-3049.
56. Cenci S, Oliva L, Cerruti F, et al. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92(5):921-931.
57. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-4916.
58. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67(4):1783-1792.
59. Zhou P, Ma X, Iyer L, Chaulagain C, Comenzo RL. One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. Blood. 2014;123(22):3440-3451.
60. Kastritis E, Terpos E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother. 2013;14(11):1477-1495.
61. Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014;124(16):2498-2506.
62. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479-1485.